Arteriosclerosis Patents (Class 514/824)
-
Patent number: 5405873Abstract: There are provided substituted acetamide derivatives represented by general formula (I): ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12, R.sup.13, n and Z are defined in the specification. The substituted acetamide derivatives strongly inhibit acylcoenzyme A cholesterol acyltransferase (ACTA) and are expected to be effective for the treatment and prevention of hypercholesterolemia, hyperlipemia and arteriosclerosis.Type: GrantFiled: September 7, 1993Date of Patent: April 11, 1995Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Yoshikazu Iwasawa, Hiromi Hattori, Yasufumi Nagata, Akiko Shimizu, Yoshio Sawasaki
-
Patent number: 5393776Abstract: This invention relates to structurally novel acyclic tocotrienol analogs, which are useful for cholesterol/lipid lowering in cases of hypercholesterolemia and hyperlipidemia, and for atherosclerosis. Also provided are pharmaceutical compositions and a method of use employing those compositions.Type: GrantFiled: May 13, 1994Date of Patent: February 28, 1995Assignee: Bristol-Myers Squibb CompanyInventor: Bradley C. Pearce
-
Patent number: 5393775Abstract: A compound selected from those of formula (I): ##STR1## in which R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and n are as defined in the description, its optical isomers, and its addition salts thereof with a pharmaceutically-acceptable acid or base,and medicinal product containing the same for treating a mammal afflicted with a disorder connected with peroxydation processes and biosynthesis of eicosanoids.Type: GrantFiled: September 7, 1993Date of Patent: February 28, 1995Assignee: Adir et CompagnieInventors: Guillaume Le Baut, Jean-Paul Babingui, Sylvie Robert-Piessard, Pierre Renard, Daniel-henri Caignard, jean-Francois Renaud de la Faverle, Gerard Adam
-
Patent number: 5391551Abstract: A method of lowering blood lipid levels, comprising administering to a patient in need of such treatment an effective amount of a compound of formula I ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is hydroxy or a group capable of being removed in vivo to produce a compound of formula I wherein R.sup.1 is OH; andX and Y are the same or different and are selected from hydrogen, trifluoromethyl, fluoro, and chloro.Type: GrantFiled: May 10, 1993Date of Patent: February 21, 1995Assignee: Pfizer Inc.Inventor: Michael J. Peterson
-
Patent number: 5384332Abstract: The present invention provides novel methods of inhibiting aortal smooth muscle cell proliferation, particularly restenosis, in humans, comprising administering to a human in need of treatment an effective amount of a compound of formula I ##STR1## wherein R.sup.1 and R.sup.2 may be the same or different provided that, when R.sup.1 and R.sup.2 are the same, each is a methyl or ethyl group, and, when R.sup.1 and R.sup.2 are different, one of them is a methyl or ethyl group and the other is a benzyl group, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 11, 1994Date of Patent: January 24, 1995Assignee: Eli Lilly and CompanyInventor: Steven A. Fontana
-
Patent number: 5378692Abstract: A method of lowering lipids is disclosed wherein a patient is administered a lipid metabolism improving composition characterized by comprising a compound of the following formula: ##STR1## wherein R.sub.1 represents a hydrogen atom or a lower alkyl group; R.sub.2 and R.sub.3 are the same or different and each represents a hydroxyl group, a lower alkoxy group or an amino group, or a pharmacologically acceptable salt thereof as an active ingredient.Since the compound of the present invention lowers blood triglyceride, cholesterol and .beta.-lipoprotein levels, it is of value for ameliorating hyperlipidemia in arteriosclerotic diseases, e.g. myocardinal infarction, angina pectoris, cerebral infarction, cerebral arteriosclerosis, etc., nephrosis, hypertension, diabetes, obesity and other diseases, and prevention of various circulatory diseases.Type: GrantFiled: July 6, 1993Date of Patent: January 3, 1995Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Shinji Ohmori, Kazumi Ogata, Hideki Tsuruoka, Takahiro Sakaue, Yuuichi Isowaki, Yasuko Umegaki
-
Patent number: 5372999Abstract: The invention relates to the use of magnesium-pyridoxal-5'-phosphate-glutaminate to prepare a pharmaceutical suitable for the reduction of LDL-bound peroxides and for the prophylaxis of vascular lesions resulting therefrom in the absence of hypercholesteraemia or hyperlipidaemia.Type: GrantFiled: April 2, 1993Date of Patent: December 13, 1994Assignee: Steigerwald Arzneimittelwerk GmbHInventors: Werner Schneider, Britta Meyer, Erich F. Elstner
-
Patent number: 5362732Abstract: A novel class of pharmaceutically active boronated compounds are provided. The boronated compounds include boronated purine and pyrimidine bases and boronated nucleosides, as well as phosphate esters and oligomers thereof. The compounds are boronated at the ring nitrogen of the purine or pyrimidine base, or at a 2', 3' or 5' amino substituent of the nucleoside sugar.Type: GrantFiled: July 7, 1992Date of Patent: November 8, 1994Assignees: University of North Carolina at Chapel Hill, Boron Biologicals, Duke UnversityInventors: Bernard F. Spielvogel, Anup Sood, Iris H. Hall, Barbara R. Shaw, Jeno Tomasz
-
Patent number: 5360613Abstract: Patients with elevated blood levels of low-density lipoprotein (LDL) and total cholesterol are treated by administering .beta.-hydroxy-.beta.-methylbutyric acid (HMB) to reduce the patient's blood level of LDL and total cholesterol. HMB can be safely administered orally to humans in amounts that will significantly reduce blood levels of total cholesterol and LDL.Type: GrantFiled: October 14, 1993Date of Patent: November 1, 1994Assignee: Iowa State University Research Foundation, Inc.Inventor: Steven L. Nissen
-
Patent number: 5358959Abstract: The applicant has identified a particular class of imidazoles that inhibit endothelial cell, vascular smooth muscle cell and fibroblast proliferation. These imidazoles can be used to beneficially treat a variety of arteriosclerotic conditions.Type: GrantFiled: February 18, 1993Date of Patent: October 25, 1994Assignee: President and Fellows of Harvard UniversityInventors: Jose Halperin, Carlo Brugnara
-
Patent number: 5342853Abstract: The use of nor-verapamil and nor-gallopamil and the salts thereof with physiologically tolerated acids is disclosed for the preparation of drugs with antiarteriosclerotic properties.Type: GrantFiled: November 12, 1991Date of Patent: August 30, 1994Assignee: Knoll AGInventors: Claus D. Mueller, Liliane Unger
-
Patent number: 5334617Abstract: The present invention relates to compositions and methods for inhibiting protein aging. Accordingly, a composition is disclosed which comprises an agent or compound capable of inhibiting the formation of advanced glycosylation end products of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. Suitable agents are amino acids and their derivatives which contain an active nitrogen-containing group. Particular agents comprise lysine and mixtures thereof. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.Type: GrantFiled: January 27, 1992Date of Patent: August 2, 1994Assignees: The Rockefeller University, Alteon Inc.Inventors: Peter C. Ulrich, Anthony Cerami
-
Patent number: 5326559Abstract: The invention features a method for treating a patient suffering from accelerated atherosclerosis in a patient suffering from vascular damage, e.g., damage caused by percutaneous transluminal coronary angioplasty (PTCA), heart transplantation, or coronary vein graft. The method includes administering to the patient a molecule which is capable of specifically binding to a interleukin receptor expressed on a cell of the patient which contributes to the process of accelerated atherosclerosis. The molecule is capable of decreasing the viability of the cells.Type: GrantFiled: May 16, 1991Date of Patent: July 5, 1994Inventor: D. Douglas Miller
-
Patent number: 5326762Abstract: Amides of the formula ##STR1## wherein R.sub.1 and R.sub.2 are independently heteroaryl, X-substituted heteroaryl, X-substituted phenyl, N-substituted triazinyl or N-substituted imidazolyl;and in addition, one of R.sub.1 and R.sub.2 can be as defined above and the other can be phenyl;R.sub.3 is an alkyl chain of 2 to 25 carbon atoms, saturated or unsaturated; an alkyl chain as defined substituted by one or more substituents selected from the group consisting of phenyl, X-substituted phenyl, heteroaryl and X-substituted heteroaryl; an alkyl chain as defined interrupted by one or more groups independently selected from the group consisting of --O--, --S--, --SO--, --SO.sub.2 --, --NH--, --N(lower alkyl)--, --C(O)--, phenylene, X-substituted phenylene, heteroarylene and X-substituted heteroarylene; or an interrupted alkyl chain as defined substituted by one or more substituents selected form the group consisting of phenyl, X-substituted phenyl, heteroaryl and X-substituted heteroaryl;R.sub.Type: GrantFiled: May 19, 1992Date of Patent: July 5, 1994Assignee: Schering CorporationInventors: John Clader, Sundeep Dugar, Timothy Kogan, Bradley Tait, Wayne Vaccaro
-
Patent number: 5316766Abstract: The combination of a fibrinolytic and a prostacyclin analogue is very useful for thrombosis treatment, especially to avoid subsequent rethrombosis.Type: GrantFiled: February 6, 1990Date of Patent: May 31, 1994Assignee: Schering AktiengesellschaftInventors: Berthold Baldus, Bernhard Maass, Bernd Muller, Werner Witt
-
Patent number: 5317015Abstract: This invention relates to a method of lowering abnormally high serum cholesterol levels in the body without significantly reducing mevalonic metabolite synthesis and to novel pharmacological compositions containing as an active ingredient bisphosphonic acid and ester compounds containing a mono-, bi- or tricyclic ring linked with a bisphosphonate moiety through a basic amino alkylene group. This invention also provides novel bisphosphonate compounds and the processes for their preparation.Type: GrantFiled: May 1, 1992Date of Patent: May 31, 1994Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.Inventors: John W. Ullrich, Raymond D. Youssefyeh, Daniel L. Cheney, Christopher J. Burns
-
Patent number: 5310562Abstract: In a preferred embodiment, drugs having heretofore unknown pharmacological properties which are useful in the medicinal therapy of fibrotic disease for the reparation and prevention of fibrotic lesional tissues, such drugs including as the active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone. The pharmaceutical composition of this invention is novel as an anti-fibrotic drug, namely, as an agent for treating fibrosis. Any existing compounds have not been shown to be effective for the reparation and prevention of fibrotic lesions.Type: GrantFiled: September 21, 1992Date of Patent: May 10, 1994Inventor: Solomon B. Margolin
-
Patent number: 5308861Abstract: A therapeutic agent used for photodynamic therapy of atherosclerosis of mammals, which agent comprises at least one member of fluorescent compounds selected from the group consisting of tetrapyrrole carboxylic acids having at least one carboxyl group, corresponding di- or tetrahydrotetrapyrrole carboxylic acids, and mono-, di- or polyamides of the tetrapyrrole carboxylic acids with amino-mono- or dicarboxylic acids and their salts.Type: GrantFiled: April 29, 1992Date of Patent: May 3, 1994Assignee: Nippon Petrochemicals Company, LimitedInventors: Katsuo Aizawa, Yukari Kuroiwa
-
Patent number: 5306724Abstract: The present invention provides a method for treating atherosclerosis. The method includes the step of administering to a patient having atherosclerosis, a noncysteine, non-thiol composition that will stimulate the intracellular synthesis of glutathione. In an embodiment, the non-cysteine, non-thiol composition is L-2-oxothiazolidine-4-carboxylate. In an embodiment of the present invention, the present invention provides a method for preventing atherosclerotic lesions in a patient at risk of same. Furthermore, the present invention provides a method for preventing re-stenosis in a patient undergoing an invasive procedure to treat atherosclerosis.Type: GrantFiled: August 17, 1992Date of Patent: April 26, 1994Assignee: Clintec Nutrition CompanyInventor: Dennis I. Goldberg
-
Patent number: 5302613Abstract: This invention relates to compounds of Formula I ##STR1## which are useful as antiatherosclerotic agents and inhibitors of cell proliferation for the treatment of proliferative diseases. In addition, various compounds of Formula I are useful inhibitors of platelet aggregation.Type: GrantFiled: April 9, 1993Date of Patent: April 12, 1994Assignee: The Upjohn CompanyInventor: Joel Morris
-
Patent number: 5294543Abstract: Purified DNA comprising a sequence encoding chrysoptin.Chrysoptin can be used to alter the hemodynamic or hemostatic properties of an animal's blood by administering to the animal an effective amount of chrysoptin.Type: GrantFiled: April 8, 1992Date of Patent: March 15, 1994Assignee: The General Hospital CorporationInventors: Ethan A. Lerner, Michael R. Lerner
-
Patent number: 5294720Abstract: There are provided novel 1,4 Diamine 2,3 Dihydroxybutanes useful as antiviral agents, pharmaceutical compositions containing them and processes for preparing such compounds.Type: GrantFiled: May 31, 1991Date of Patent: March 15, 1994Assignee: The DuPont Merck Pharmaceutical Co.Inventors: Prabhakar K. Jadhav, Lawrence R. McGee, Ashok Shenvi, Carl N. Hodge
-
Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis
Patent number: 5288716Abstract: A method for prevention of atherosclerosis or for treatment of hyperlipidaemia or atherosclerosis comprises administering one of more pyridoxine derivatives to a host in need thereof.Type: GrantFiled: June 15, 1989Date of Patent: February 22, 1994Inventor: Ulrich Speck -
Patent number: 5281421Abstract: Improved oral formulations are prepared by admixing gemfibrozil with from 1 to 4%, by weight, of a pharmaceutically acceptable surfactant having an HLB value of from about 10 to about 50.Type: GrantFiled: April 16, 1992Date of Patent: January 25, 1994Assignee: Warner-Lambert CompanyInventors: Isaac Ghebre-Sellassie, Mahdi B. Fawzi
-
Patent number: 5278189Abstract: A method is provided for prevention and treatment of cardiovascular disease, such as atherosclerosis, by administering therapeutically effective dosages of a drug comprised of ascorbate, lipoprotein(a) binding inhibitors, and antioxidants.Type: GrantFiled: July 24, 1990Date of Patent: January 11, 1994Inventors: Matthias W. Rath, Linus C. Pauling
-
Patent number: 5272174Abstract: Derivatives of ML-236B carboxylic acid, its salts and esters and corresponding lactone have a hydroxy group at the 3"-position and optionally also at the 6'-position. These derivatives may be prepared by the enzymatic hydroxylation of a corresponding ML-236B compound employing an enzyme produced by a microorganism of the genus Streptomyces or Amycolata, especially Streptomyces sp. SANK 62285, Streptomyces sp. SANK 62385, Streptomyces sp. SANK 62485, Streptomyces sp. SANK 62585, Amycolata autotrophica SANK 62781. Amycolata autotrophica subsp. canberrica SANK 62882 or Amycolata autotrophica subsp. amethystina SANK 62981. These derivatives have the ability to inhibit cholesterol biosynthesis.Type: GrantFiled: July 23, 1992Date of Patent: December 21, 1993Assignee: Sankyo Company, LimitedInventors: Kouhei Furuya, Takao Okazaki, Yoshio Tsujita, Seigo Iwado, Kiyoshi Hamano, Masao Kuroda, Jun Yoshikawa, Toshiaki Iwai, Kunio Nakano
-
Patent number: 5268181Abstract: The invention provides a therapeutic method to treat hyperlipidemia by administering to a human patient a single daily dose of a prolonged release dosage form of niacin, so that nocturnal cholesterol synthesis is effectively suppressed.Type: GrantFiled: June 29, 1992Date of Patent: December 7, 1993Assignee: Upsher-Smith Laboratories, Inc.Inventors: Victoria A. O'Neill, Kenneth L. Evenstad
-
Patent number: 5268367Abstract: A cholesterol or body weight regulating material comprising an enzyme resistant starch is disclosed. A composition which contains said enzyme resistant starch is also disclosed. A food, food material, and beverage, containing said enzyme resistant starch are further disclosed. A method for regulating cholesterol or body weight is still further disclosed. Those are effective not only for lowering cholesterol level, but for preventing obesity.Type: GrantFiled: December 30, 1991Date of Patent: December 7, 1993Assignee: Kanegafuchi Kagaku Kogyo Kabushiki KaishaInventors: Toshiaki Miwa, Takayoshi Hidaka, Yoji Hisada, Takehiko Ohfuji, Y. Pomeranz
-
Patent number: 5260272Abstract: Polypeptides of the formulapoly (X).sub.m (Y).sub.n,whereinX is selected from the group consisting of aspartate, glutamate, glutamine, asparagine, mixtures and block polymers thereof,Y is selected from the group consisting of phosphoserine, sulfoserine, phosphohomoserine, phosphotyrosine, phosphothreonine, phosphoglutamine, phosphoasparagine, serine, alanine, dehydroalanine and mixtures thereof,m=5-199 andn=1-10have been demonstrated to inhibit mineral deposition, and can be employed in the inhibition of mineral deposition in both in vitro and in vivo applications. Serine-containing polypeptides can be thermally synthesized by combining the necessary amino acid residues in a reaction vessel, eliminating oxygen to preclude charring, and heating said reaction vessel in a heating medium to a temperature of about 155.degree. C.Type: GrantFiled: March 29, 1991Date of Patent: November 9, 1993Assignee: University of South AlabamaInventors: Julie Donachy, Steven Sikes
-
Patent number: 5260305Abstract: A pharmaceutical combination is provided which includes an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, which is pravastatin and a pharmaceutical which reduces serum cholesterol and/or inhibits cholesterol biosynthesis by a mechanism other than inhibiting production of the enzyme HMG CoA reductase, namely, nicotinic acid (niacin) or related acid. A method for reducing serum cholesterol or inhibiting formation of or treating atherosclerosis using the above combination without causing drug-induced myopathy or rhabdomyolysis, is also provided.Type: GrantFiled: June 18, 1992Date of Patent: November 9, 1993Assignee: E. R. Squibb & Sons, Inc.Inventor: Leonard G. Dennick
-
Patent number: 5258181Abstract: The present invention relates to compositions comprising psyllium fiber and peanut paste, and the use of these compositions as laxatives and/or for cholesterol reduction benefits. The compositions are a convenient, portable, highly palatable, and well tolerated dosage form for administering psyllium fiber.Type: GrantFiled: March 2, 1992Date of Patent: November 2, 1993Assignee: The Procter & Gamble CompanyInventors: Melissa M. Cregier, John A. Colliopoulos
-
Patent number: 5254593Abstract: The present invention relates to compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with the carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.Type: GrantFiled: December 16, 1991Date of Patent: October 19, 1993Assignee: The Rockefeller UniversityInventors: Peter C. Ulrich, Anthony Cerami
-
Patent number: 5254585Abstract: The present invention relates to the use of peroxidized lipids, having a degree of peroxidation of between 50 and 200 milliequivalents per kilogram, preferably of between 50 and 150 milliequivalents per kilogram, for the preparation of a pharmaceutical composition intended for the treatment of circulatory insufficiencies, and in particular male sexual asthenia, by local application.Type: GrantFiled: December 30, 1991Date of Patent: October 19, 1993Assignee: Laboratoires CarileneInventor: Stephane Desjonqueres
-
Patent number: 5254549Abstract: Pharmaceutically-active BHT-omega pyridyl ethers of the formula selected from BHT-omega-pyridyl ether compounds of the formula: ##STR1## wherein m=1,3for m=1, .SIGMA.=6-9for m=3, .SIGMA.=5-11Sum (.SIGMA.)=[m+n+1 (for oxygen)]wherein the bond between the two carbon atoms of the (CH.sub.2).sub.n moiety most closely adjacent the pyridine ring is a single, double, or triple bond, and pharmaceutically-acceptable acid addition salts thereof, pharmaceutical compositions thereof, and a method of combating lipidemia and atherosclerosis therewith, are disclosed.Type: GrantFiled: December 19, 1991Date of Patent: October 19, 1993Assignee: Merz & Co. GmbH & Co.Inventors: Markus R. Gold, Panayiotis Jarglis, Heinz Junglas, Juergen H. Leimner, Dezsoe Peteri, Guenter P. Quack, Josef Strohmeier, Petra M. Wulfroth
-
Patent number: 5248688Abstract: A method and substrate composition for treating atherosclerosis are provided. The method involves parenterally administering the substrate composition as an aqueous solution to substantially lower plasma cholesterol and substantially reverse arterial plaque deposition and degenerative changes associated with atherosclerosis. The substrate compositions include mixtures of biologically active levorotatory amino acids as the antiatherosclerotic agent.Type: GrantFiled: March 4, 1991Date of Patent: September 28, 1993Assignee: Dudrick Medical Research Fund I, Ltd.Inventor: Stanley J. Dudrick
-
Patent number: 5246960Abstract: Racemic compounds of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and n are as described herein, enantiomers and diastereomers thereof, and salts of these esters with weak acids, are described. These compounds inhibit pancreas lipase and are useful agents in the treatment of obesity, hyperlipaemia, atherosclerosis and arteriosclerosis.Type: GrantFiled: September 14, 1992Date of Patent: September 21, 1993Assignee: Hoffmann-La Roche Inc.Inventors: Pierre Barbier, Fernand Schneider, Ulrich Widmer
-
Patent number: 5240702Abstract: In accordance with the present invention, a method is provided for treating stroke. More particularly, the present invention relates to a method for treating stroke comprising injecting a non-emulsion, homogeneous solution of certain ethylene oxide-propylene oxide condensation surface-active copolymers. The surface-active copolymer can be an ethylene oxide-propylene oxide condensation product with the following general formula:HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (C.sub.2 H.sub.4 O).sub.b Hwherein a is an integer such that the hydrophobe represented by (C.sub.3 H.sub.6 O) has a molecular weight of approximately 950 to 4000 daltons, preferably approximately 1200 to 3500 daltons, and b is an integer such that the hydrophile portion represented by (C.sub.2 H.sub.4 O) constitutes approximately 50% to 90% by weight of the compound.Type: GrantFiled: December 4, 1992Date of Patent: August 31, 1993Assignee: Emory UniversityInventors: Robert L. Hunter, Alexander Duncan
-
Patent number: 5234952Abstract: Lipids obtained from blackcurrant seed are used for reducing thrombogenicity of blood vessels in humans.Type: GrantFiled: May 28, 1992Date of Patent: August 10, 1993Assignee: Nestec S.A.Inventors: Gayle Crozier-Willi, Mathilde Fleith, Michael Buchanan
-
Patent number: 5234954Abstract: A method for treatment of hyperlipemia which comprises administering, to a subject in need of such treatment, a 15-keto-prostaglandin compound in an amount, effective in decreasing lipid concentration in the blood.Type: GrantFiled: June 15, 1992Date of Patent: August 10, 1993Assignee: K.K. Ueno Seiyaku Oyo KenkyujoInventors: Ryuji Ueno, Hiroyoshi Osama
-
Patent number: 5234946Abstract: The substituted alkylamine derivatives represented by formula (I) ##STR1## wherein R.sup.1 represents (a) substituted or unsubstituted C.sub.2-6 alkenyl group, (b) substituted or unsubstituted C.sub.3-6 cycloalkenyl group, (c) substituted or unsubstituted C.sub.2-6 alkynyl group, (d) substituted or unsubstituted aryl group, (e) substituted or unsubstituted heterocyclic group, (f) fused heterocyclic group which may be substituted, or (g) group represented by the formula Ru.sup.11 -Ar wherein R.sup.11 is a heterocyclic group and Ar is a 5- or 6-membered aromatic ring which may contain a hetero N, O or S atom, and which may be substituted; ##STR2## represents a 5- or 6-membered aromatic ring which may contain a hetero N, O or S atom, and may be substituted by R.sup.7,X and Y are linking groups,R.sup.2 is H or lower alkyl,R.sup.3 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl or lower cycloalkyl,R.sup.4 and R.sup.5 are independently hydrogen or halogen atoms,R.sup.Type: GrantFiled: August 30, 1991Date of Patent: August 10, 1993Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Hiroshi Takezawa, Masahiro Hayashi, Yoshikazu Iwasawa, Masaaki Hosoi, Yoshiaki Iida, Yoshimi Tsuchiya, Masahiro Horie, Toshio Kamei
-
Patent number: 5232698Abstract: Psyllium husk-containing drink mix compositions comprising small particle size psyllium husk and edible, water soluble salts. The edible, water soluble salts are present at a level sufficient to reduce the gellation rate of the psyllium husk when dispersed in an aqueous solution.Type: GrantFiled: June 12, 1992Date of Patent: August 3, 1993Assignee: The Proctor & Gamble CompanyInventor: Lee A. Hord
-
Patent number: 5231090Abstract: The present invention relates to a method of modifying serum cholesterol levels in a mammal by topically administering to the skin of the mammal an effective amount of at least one phospholipid. Atherosclerosis, and related complications, can be treated, or prevented, using the present method.Type: GrantFiled: July 30, 1990Date of Patent: July 27, 1993Assignee: University of MiamiInventors: Sung L. Hsia, Jin L. He
-
Patent number: 5219888Abstract: A method to increase plasma high density lipoprotein levels for the treatment and prevention of coronary artery disease by administering a therapeutic amount of a retinoid of the general formula: ##STR1##Type: GrantFiled: March 31, 1992Date of Patent: June 15, 1993Assignee: American Cyanamid CompanyInventors: Andrew S. Katocs, Jr., Elwood Largis, Sotirios K. Karathanasis
-
Patent number: 5217992Abstract: This invention relates to the use of tocotrienol, gamma-tocotrienol and delta-tocotrienol in reducing hypercholesterolemia, hyperlipidemia and thromboembolic disorders in mammals. [The isolation of these tocotrienols from natural sources and their chemical synthesis is disclosed.] The chemical synthesis of these tocotrienols is disclosed. The present invention also relates to prodrugs and pharmaceutical compositions of gamma-tocotrienol, delta-tocotrienol and tocotrienol and uses thereof.Type: GrantFiled: September 17, 1990Date of Patent: June 8, 1993Assignee: Bristol-Myers Squibb CompanyInventors: John J. Wright, Bradley C. Pearce, Rex Parker, Asaf A. Qureshi
-
Patent number: 5214206Abstract: The present invention provides pharmaceutically useful compounds which are aminosulfonyl urea compounds which are ACAT inhibitors rendering them useful in controlling blood cholesterol levels, pharmaceutical compositions and methods of using the ACAT inhibitors and closely related compounds which are also aminosulfonyl urea compounds.Type: GrantFiled: August 19, 1991Date of Patent: May 25, 1993Assignee: Warner-Lambert CompanyInventors: Joseph A. Picard, Drago R. Sliskovic
-
Patent number: 5211947Abstract: A method for lowering the blood cholesterol levels in mammals and humans by administering GM-CSF is disclosed.Type: GrantFiled: December 16, 1988Date of Patent: May 18, 1993Assignee: Schering CorporationInventors: Melvin D. Brannan, Hugh E. Black
-
Patent number: 5210073Abstract: A composition and method for the treatment of inflammation, rheumatism, autoimmune disease, ischemic damage of organs, drug toxicity and arteriosclerosis comprising human ADF is disclosed.Type: GrantFiled: September 28, 1990Date of Patent: May 11, 1993Assignees: Ajinomoto Co., Inc., Junji YodoiInventors: Junji Yodoi, Atsushi Uchida, Yutaka Tagaya, Akira Mitsui, Tadashi Hirakawa
-
Patent number: 5208258Abstract: A method of preparing compactin and mevinolin, ketoacid, enone, and glutarate analogs thereof, and related compounds. The compounds are prepared in substantially enantiomerically pure form using a structurally convergent synthesis. Total syntheses of (+)-compactin, (+)-mevinolin and related compounds are provided. Novel compounds are identified, several of which show significant anti-hypercholesterolemic activity.Type: GrantFiled: April 17, 1990Date of Patent: May 4, 1993Assignee: The Regents of the University of CaliforniaInventors: Clayton H. Heathcock, Terry J. Rosen
-
Patent number: 5202029Abstract: A process for the purification of an HMG-CoA reductase inhibitor employing preparative high performance liquid chromatography is described.Type: GrantFiled: March 13, 1991Date of Patent: April 13, 1993Assignee: Caron Kabushiki KaishaInventors: Peter N. Haytko, Arthur S. Wildman, Jr.
-
Patent number: H1286Abstract: A method is provided for treating peripheral atherosclerotic disease (arteriosclerosis obliterans) and/or intermittent claudication employing a cholesterol lowering drug such as an HMG CoA reductase inhibitor alone and/or an inhibitor of the enzyme squalene synthetase and optionally a pharmaceutical which reduces serum cholesterol by a mechanism other than inhibiting production of the enzyme HMG CoA reductase or the enzyme squalene synthetase, for example, probucol or gemfibrozil; employing an ACE inhibitor alone such as captopril or ceranapril; or a combination of a cholesterol lowering drug and an ACE inhibitor.Type: GrantFiled: October 18, 1990Date of Patent: February 1, 1994Assignee: E. R. Squibb & Sons, Inc.Inventors: Martin Eisman, Mark E. McGovern